A new drug intended to make it easier to clear mucus from the lungs of people with cystic fibrosis showed promising results in a Phase 2 clinical trial. The drug, called SPX-101, blocks the overactive sodium channels that line CF lung cells.
Site Search
Showing 61 - 70 of 259 results
News
|
|
2 min read
News
|
|
2 min read
Today Vertex Pharmaceuticals Inc. announced the two next-generation CFTR modulator candidates that will progress into Phase 3 clinical trials.
News
|
|
4 min read
News
|
|
2 min read
News
|
|
5 min read
The Cystic Fibrosis Foundation has followed the health care reform discussion closely. While the Foundation has not taken a position on any particular health reform bill, we have consistently and aggressively encouraged officials to include specific reforms that are important for the treatment of cystic fibrosis.
News
|
|
2 min read
News
|
|
2 min read
News
|
|
1 min read
News
|
|
2 min read